Vision Clinical Trial - GABA Levels in the Brains of Blind People

Status Completed

Clinical Trial Summary

In blind individuals, the occipital cortex becomes capable of processing tactile and auditory information, a phenomenon described as crossmodal plasticity. GABA is the major inhibitory neurotransmitter in the brain and a possible candidate to mediate this form of human plasticity. We intend to use magnetic resonance spectroscopy (MRS) to measure GABA and hypothesize that GABA levels in the occipital cortex of blind humans will be lower than in sighted controls. Such decrease could possibly mediate compensatory changes in the occipital cortex of the blind.

Objective

Early blind subjects exhibit better tactile acuity than late blinds or sighted individuals. The purpose of the study is the determine GABA levels in the human occipital cortex after long-term light deprivation (blindness).

Study Population

Our experiments will make use of early blind, late blind, and sighted control subjects.

Design

Subject will be identified and will receive clinical and neurological examinations at the NIH. MRS studies will be performed at NIH MRI Center with 3Tesla Magnet. Each subject head will be positioned in an adjustable holder (designed for minimal motion and maximal comfort) such that a flat coil lay just below the occipital cortex. The sequence has been described before [33]. The individuals who perform the data analysis will be blind to the purpose of the experiments.

Outcome measures

The concentration of GABA from the 14 ml voxel over the visual cortex will be measured. Edited proton spectrum of GABA will be compared with the edited sub spectrum of creatine for a concentration reference.

Clinical Trial Description

In blind individuals, the occipital cortex becomes capable of processing tactile and auditory information, a phenomenon described as crossmodal plasticity. GABA is the major inhibitory neurotransmitter in the brain and a possible candidate to mediate this form of human plasticity. We intend to use magnetic resonance spectroscopy (MRS) to measure GABA and hypothesize that GABA levels in the occipital cortex of blind humans will be lower than in sighted controls. Such decrease could possibly mediate compensatory changes in the occipital cortex of the blind.

Objective

Early blind subjects exhibit better tactile acuity than late blinds or sighted individuals. The purpose of the study is the determine GABA levels in the human occipital cortex after long-term light deprivation (blindness).

Study Population

Our experiments will make use of early blind, late blind, and sighted control subjects.

Design

Subjects will be identified and will receive clinical and neurological examinations at the NIH. MRS studies will be performed at NIH MRI Center with 3Tesla Magnet. Each subject head will be positioned in an adjustable holder (designed for minimal motion and maximal comfort) such that a flat coil lay just below the occipital cortex. The sequence has been described before. The individuals who perform the data analysis will be blind to the purpose of the experiments.

Outcome measures

The concentration of GABA from the 14 ml voxel over the visual cortex will be measured. Edited proton spectrum of GABA will be compared with the edited sub spectrum of creatine for a concentration reference. ;

Study Design

Related Conditions & MeSH terms

Blind
Vision

Clinical Trial Details

NCT number	NCT00357409
Study type	Observational
Source	National Institutes of Health Clinical Center (CC)
Contact
Status	Completed
Phase	N/A
Start date	February 11, 2002
Completion date	March 3, 2008

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05419713` - Intermediate Visual Space Perception	N/A
Completed	`NCT00713076` - Wettability of Contact Lenses With a Multi-Purpose Solution	N/A
Completed	`NCT04065061` - Erinacine A-enriched Hericium Erinaceus Mycelia for Improvement of Recognition, Vision, and Functional MRI Alterations	N/A
Withdrawn	`NCT00886249` - Depth of Focus Comparison Between Acrysof IQ and Acrysof Natural IOLs
Completed	`NCT00591110` - Project inCharge: Increasing the Rate of Comprehensive Eye Care Utilization by Older African Americans Through Community-Based Eye Health Education Program	N/A
Completed	`NCT02033200` - Safety Study Looking at the Effects of Stendra on Vision	Phase 4
Withdrawn	`NCT01062672` - Functional Neuroimaging of Cortical Plasticity in the Human Visual System
Recruiting	`NCT03884985` - Eye Movements, Visual Perception and Attention	N/A
Completed	`NCT01057966` - Bioavailability of Nutrients Contained in Softgel Capsules vs Tablets	Phase 4
Completed	`NCT01138228` - Does the VTS1000 Infra Red Vein Imager Allow Better Identification of Veins Than Normal Eyesight?	N/A
Recruiting	`NCT00768586` - Analysis of the Early Development of the Visual Function in Extreme Premature Infants Under 28th Weeks of Gestation	N/A
Completed	`NCT05533658` - The Effects of VisionPure™ on Indices of Vision Health and Cognitive Function	N/A
Recruiting	`NCT04332783` - Isolating and Mitigating Sequentially Dependent Perceptual Errors in Clinical Visual Search	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.